Collateral sensitivity as a strategy against cancer multidrug resistance
Top Cited Papers
- 30 April 2012
- journal article
- review article
- Published by Elsevier BV in Drug Resistance Updates
- Vol. 15 (1-2), 98-105
- https://doi.org/10.1016/j.drup.2012.03.002
Abstract
No abstract availableKeywords
Funding Information
- the Intramural Research Program of the National Institutes of Health, National Cancer Institute
This publication has 73 references indexed in Scilit:
- Synthesis and Structure–Activity Evaluation of Isatin-β-thiosemicarbazones with Improved Selective Activity toward Multidrug-Resistant Cells Expressing P-GlycoproteinJournal of Medicinal Chemistry, 2011
- Collateral Sensitivity of Multidrug-Resistant Cells to the Orphan Drug TioproninJournal of Medicinal Chemistry, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- The Selectivity of Austocystin D Arises from Cell-Line-Specific Drug Activation by Cytochrome P450 EnzymesJournal of Natural Products, 2011
- Regulation of cancer cell metabolismNature Reviews Cancer, 2011
- Antitumor Agents. 280. Multidrug Resistance-Selective Desmosdumotin B AnaloguesJournal of Medicinal Chemistry, 2010
- Is resistance useless? Multidrug resistance and collateral sensitivityTrends in Pharmacological Sciences, 2009
- Structure of a multidrug transporterNature Biotechnology, 2009
- Synthesis, Activity, and Pharmacophore Development for Isatin-β-thiosemicarbazones with Selective Activity toward Multidrug-Resistant CellsJournal of Medicinal Chemistry, 2009
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006